Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2851) 2851
Publication (363) 363
Conference Proceeding (103) 103
Book Review (34) 34
Magazine Article (12) 12
Book Chapter (3) 3
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pembrolizumab (2888) 2888
oncology (1596) 1596
nivolumab (1416) 1416
immunotherapy (1369) 1369
index medicus (1332) 1332
humans (927) 927
ipilimumab (853) 853
cancer (845) 845
melanoma (808) 808
chemotherapy (803) 803
open-label (605) 605
metastasis (526) 526
patients (502) 502
tumors (462) 462
docetaxel (457) 457
lung cancer (442) 442
care and treatment (418) 418
female (415) 415
male (414) 414
pd-1 (409) 409
survival (389) 389
immunology (387) 387
pd-l1 (385) 385
middle aged (371) 371
immune checkpoint (364) 364
safety (360) 360
apoptosis (352) 352
aged (349) 349
cancer therapies (347) 347
clinical trials (344) 344
multicenter (337) 337
therapy (324) 324
metastases (289) 289
blockade (287) 287
cell lung-cancer (279) 279
pd-1 protein (275) 275
metastatic melanoma (262) 262
research (256) 256
expression (255) 255
respiratory system (252) 252
programmed cell death 1 receptor - antagonists & inhibitors (250) 250
pd-l1 protein (244) 244
lymphocytes (241) 241
analysis (236) 236
adult (234) 234
atezolizumab (233) 233
pd-1 blockade (223) 223
lung cancer, non-small cell (215) 215
antibodies, monoclonal - therapeutic use (213) 213
biomarkers (211) 211
advanced melanoma (209) 209
cell death (203) 203
immunotherapy - methods (203) 203
treatment outcome (202) 202
prognosis (201) 201
mutation (200) 200
antineoplastic agents - therapeutic use (199) 199
melanoma - drug therapy (199) 199
drug therapy (197) 197
immune checkpoint inhibitors (197) 197
ligands (197) 197
neoplasms. tumors. oncology. including cancer and carcinogens (197) 197
medical research (193) 193
antibodies, monoclonal, humanized - therapeutic use (192) 192
checkpoint inhibitors (183) 183
aged, 80 and over (182) 182
immunohistochemistry (175) 175
anti-pd-1 (172) 172
non-small cell lung carcinoma (172) 172
medicine, research & experimental (171) 171
medicine & public health (170) 170
non-small cell lung cancer (169) 169
medical prognosis (165) 165
antibodies (161) 161
adverse events (159) 159
antineoplastic agents, immunological - therapeutic use (156) 156
carcinoma (154) 154
review (151) 151
toxicity (151) 151
health aspects (150) 150
cytotoxicity (148) 148
pharmacology & pharmacy (148) 148
lung neoplasms - drug therapy (147) 147
usage (147) 147
lymphocytes t (146) 146
t-cells (146) 146
programmed cell death 1 receptor - immunology (145) 145
nsclc (143) 143
trial (142) 142
immune system (141) 141
antibodies, monoclonal, humanized - adverse effects (138) 138
article (136) 136
inhibitors (135) 135
antibody (132) 132
antibodies, monoclonal - adverse effects (128) 128
case report (125) 125
hematology (124) 124
melanoma - pathology (124) 124
antigens (122) 122
carcinoma, non-small-cell lung - drug therapy (122) 122
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2822) 2822
German (40) 40
French (39) 39
Korean (10) 10
Russian (7) 7
Spanish (7) 7
Japanese (3) 3
Czech (2) 2
Icelandic (1) 1
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Cochrane Rapid Reviews: Immun-Checkpoint-Inhibitor Pembrolizumab vs. Chemotherapie zur Behandlung von fortgeschrittenen Urothelkarzinomen
by D Wilborn and S Schmidt
Der Urologe. Ausg. A, ISSN 0340-2592, 01/2019, Volume 58, Issue 1, pp. 45 - 48
Pembrolizumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer: Time to Change Clinical Practice? Reply
by Necchi, A and Montorsi, F
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2019, Volume 37, Issue 11, pp. 940 - 940
PEMBROLIZUMAB | ONCOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma
by Chesney, Jason and Puzanov, Igor and Collichio, Frances and Singh, Parminder and Milhem, Mohammed M and Glaspy, John and Hamid, Omid and Ross, Merrick and Friedlander, Philip and Garbe, Claus and Logan, Theodore F and Hauschild, Axel and Lebbé, Celeste and Chen, Lisa and Kim, Jenny J and Gansert, Jennifer and Andtbacka, Robert H.I and Kaufman, Howard L
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 17, pp. 1658 - 1667
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II... 
ONCOLOGY | NIVOLUMAB | PEMBROLIZUMAB | Rapid Communications
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Komplette Remission eines Patienten mit metastasierten Uveamelanom nach initialem Progress unter Immuntherapie mit Pembrolizumab
by Camila Toledo Stauner and Konstantin Drexler and Mark Berneburg and Sebastian Haferkamp
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 11/2018, Volume 16, Issue 11, pp. 1376 - 1378
Pembrolizumab | Remission
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
by Larkin, James and Minor, David and D'Angelo, Sandra and Neyns, Bart and Smylie, Michael and Miller, Wilson H and Gutzmer, Ralf and Linette, Gerald and Chmielowski, Bartosz and Lao, Christopher D and Lorigan, Paul and Grossmann, Kenneth and Hassel, Jessica C and Sznol, Mario and Daud, Adil and Sosman, Jeffrey and Khushalani, Nikhil and Schadendorf, Dirk and Hoeller, Christoph and Walker, Dana and Kong, George and Horak, Christine and Weber, Jeffrey
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4, pp. 383 - 390
Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment with... 
ACQUIRED-RESISTANCE | PEMBROLIZUMAB | ONCOLOGY | COMBINATION | IPILIMUMAB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines
by Ettinger, David S and Wood, Douglas E and Akerley, Wallace and Bazhenova, Lyudmila A and Borghaei, Hossein and Camidge, David Ross and Cheney, Richard T and Chirieac, Lucian R and D'Amico, Thomas A and Dilling, Thomas J and Chris Dobelbower, M and Govindan, Ramaswamy and Hennon, Mark and Horn, Leora and Jahan, Thierry M and Komaki, Ritsuko and Lackner, Rudy P and Lanuti, Michael and Lilenbaum, Rogerio and Lin, Jules and Loo, Billy W and Martins, Renato and Otterson, Gregory A and Patel, Jyoti D and Pisters, Katherine M and Reckamp, Karen and Riely, Gregory J and Schild, Steven E and Shapiro, Theresa A and Sharma, Neelesh and Stevenson, James and Swanson, Scott J and Tauer, Kurt and Yang, Stephen C and Gregory, Kristina and Hughes, Miranda
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 03/2016, Volume 14, Issue 3, pp. 255 - 264
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines... 
PEMBROLIZUMAB | ONCOLOGY | NIVOLUMAB | IMMUNOTHERAPY | SAFETY | DOCETAXEL
Journal Article
Details down arrow
7. Full Text Generalised morphea induced by pembrolizumab
by Herrscher, Hugo and Tomasic, Gorana and Castro Gordon, Alicia
European Journal of Cancer, ISSN 0959-8049, 07/2019, Volume 116, pp. 178 - 181
ONCOLOGY | Scleroderma | Pembrolizumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib
by Chen, Chia-Yu and Chiu, Chang-Fang and Bai, Li-Yuan
European Journal of Cancer, ISSN 0959-8049, 05/2019, Volume 113, pp. 69 - 71
ONCOLOGY | Lesions | Pembrolizumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Hidden cost of pembrolizumab therapy
by Gnanapavan, Sharmilee
Multiple Sclerosis Journal, ISSN 1352-4585, 6/2019, Volume 25, Issue 7, pp. 1008 - 1009
Pembrolizumab | demyelination | checkpoint inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1–Positive Lung Cancer
by Varkaris, Andreas and Sehgal, Kartik and Rangachari, Deepa and Costa, Daniel B
Journal of Thoracic Oncology, ISSN 1556-0864, 02/2019, Volume 14, Issue 2, pp. e34 - e36
ONCOLOGY | RESPIRATORY SYSTEM | PEMBROLIZUMAB
Journal Article
Details down arrow
11. Full Text Multiple “halo nevi” occurring during pembrolizumab treatment for metastatic melanoma
by Nicolétis‐Lombart, Irène and Kervarrec, Thibault and Zaragoza, Julia and Machet, Marie Christine and Samimi, Mahtab
International Journal of Dermatology, ISSN 0011-9059, 06/2019, Volume 58, Issue 6, pp. 739 - 741
Pembrolizumab | Melanoma | Metastases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Pathological complete response after neoadjuvant pembrolizumab and radiation
by Mynard, J. N and Conry, R. M and De Los Santos, J and Gordetsky, J. B and Contreras, C. M
Clinical and Experimental Dermatology, ISSN 0307-6938, 07/2019, Volume 44, Issue 5, pp. 570 - 573
Click here for the corresponding questions to this CME article. 
DERMATOLOGY | Radiation | Pembrolizumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text A case of pembrolizumab‐induced localized organizing pneumonia
by Arays, R and Wang, P
Scandinavian Journal of Immunology, ISSN 0300-9475, 07/2018, Volume 88, Issue 1, pp. e12677 - n/a
Pembrolizumab is a monoclonal antibody directed against programmed cell death 1 (PD-1) which is an important immune-checkpoint receptor that is expressed by... 
ADVERSE EVENTS | IMMUNOLOGY | Pembrolizumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy
by Irimada, Moyuka and Fujimura, Taku and Kambayashi, Yumi and Tsukada, Akira and Takahashi, Toshiya and Hashimoto, Akira and Aiba, Setsuya
The Journal of Dermatology, ISSN 0385-2407, 07/2019, Volume 46, Issue 7, pp. e256 - e258
Melanoma | Pembrolizumab | Rhabdomyolysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text From choosing wisely to using wisely: Increasing the value of cancer care through clinical research
by Lichter, Allen S
Journal of Clinical Oncology, ISSN 0732-183X, 2018, Volume 36, Issue 14, pp. 1387 - 1388
IBRUTINIB | PEMBROLIZUMAB | PHARMACOKINETICS | ONCOLOGY | FOOD
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a Molecular Subtype Approach to Bladder Cancer is Also Needed
by Eriksson, Pontus and Sjödahl, Gottfrid and Liedberg, Fredrik
European Urology, ISSN 0302-2838, 02/2019, Volume 75, Issue 2, pp. e37 - e38
UROLOGY & NEPHROLOGY | MULTICENTER | PEMBROLIZUMAB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Complete response to pembrolizumab after initial progress in a patient with metastatic uveal melanoma
by Camila Toledo Stauner and Konstantin Drexler and Mark Berneburg and Sebastian Haferkamp
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 11/2018, Volume 16, Issue 11, pp. 1376 - 1378
Pembrolizumab | Melanoma | Metastases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Nivolumab plus ipilimumab in patients with advanced melanoma: Updated survival, response, and safety data in a phase i dose-escalation study
by Callahan, Margaret K and Kluger, Harriet and Postow, Michael A and Segal, Neil H and Lesokhin, Alexander and Atkins, Michael B and Kirkwood, John M and Krishnan, Suba and Bhore, Rafia and Horak, Christine and Wolchok, Jedd D and Sznol, Mario
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4, pp. 391 - 398
Purpose The clinical activity observed in a phase I dose-escalation study of concurrent therapy with nivolumab (NIVO) and ipilimumab (IPI) in patients with... 
UNTREATED MELANOMA | DABRAFENIB | PEMBROLIZUMAB | MONOTHERAPY | ONCOLOGY | TRAMETINIB | Original Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Navigating through new, first-line treatment options for lung cancer
by Solomon, Benjamin
Journal of Oncology Practice, ISSN 1554-7477, 09/2018, Volume 14, Issue 9, pp. 539 - 540
ONCOLOGY | PEMBROLIZUMAB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients
by Kawai, Taketo and Sato, Yusuke and Makino, Katsuhiro and Yamada, Daisuke and Yamada, Yuta and Nomiya, Akira and Nakamura, Masaki and Suzuki, Motofumi and Igawa, Yasuhiko and Kume, Haruki
European Journal of Cancer, ISSN 0959-8049, 07/2019, Volume 116, pp. 114 - 115
ONCOLOGY | NIVOLUMAB | ASSOCIATION | Urothelial cancer | Pembrolizumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.